MAGLE Stock Overview
Operates as a contract development and manufacturing organization that serves pharmaceutical and medical device industry on a contract basis in Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Magle Chemoswed Holding AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 43.60 |
| 52 Week High | SEK 49.80 |
| 52 Week Low | SEK 21.40 |
| Beta | 0.63 |
| 11 Month Change | 28.99% |
| 3 Month Change | 31.33% |
| 1 Year Change | 32.12% |
| 33 Year Change | 12.08% |
| 5 Year Change | n/a |
| Change since IPO | 112.58% |
Recent News & Updates
Market Participants Recognise Magle Chemoswed Holding AB (publ)'s (STO:MAGLE) Earnings Pushing Shares 37% Higher
Jun 26
Magle Chemoswed Holding (STO:MAGLE) Has A Pretty Healthy Balance Sheet
Jun 19Magle Chemoswed Holding's (STO:MAGLE) Earnings Are Of Questionable Quality
Apr 26Earnings Tell The Story For Magle Chemoswed Holding AB (publ) (STO:MAGLE) As Its Stock Soars 28%
Mar 29Recent updates
Market Participants Recognise Magle Chemoswed Holding AB (publ)'s (STO:MAGLE) Earnings Pushing Shares 37% Higher
Jun 26Magle Chemoswed Holding (STO:MAGLE) Has A Pretty Healthy Balance Sheet
Jun 19Magle Chemoswed Holding's (STO:MAGLE) Earnings Are Of Questionable Quality
Apr 26Earnings Tell The Story For Magle Chemoswed Holding AB (publ) (STO:MAGLE) As Its Stock Soars 28%
Mar 29Magle Chemoswed Holding AB (publ)'s (STO:MAGLE) Price In Tune With Earnings
Oct 05Should You Be Impressed By Magle Chemoswed Holding AB (publ)'s (STO:MAGLE) ROE?
Jan 22Shareholder Returns
| MAGLE | SE Life Sciences | SE Market | |
|---|---|---|---|
| 7D | -4.8% | 1.5% | 0.2% |
| 1Y | 32.1% | 12.7% | 12.6% |
Return vs Industry: MAGLE exceeded the Swedish Life Sciences industry which returned 15.9% over the past year.
Return vs Market: MAGLE exceeded the Swedish Market which returned 14.1% over the past year.
Price Volatility
| MAGLE volatility | |
|---|---|
| MAGLE Average Weekly Movement | 7.7% |
| Life Sciences Industry Average Movement | 7.7% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in SE Market | 12.3% |
| 10% least volatile stocks in SE Market | 3.4% |
Stable Share Price: MAGLE's share price has been volatile over the past 3 months.
Volatility Over Time: MAGLE's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1944 | 78 | Justin Pierce | www.maglechemoswed.com |
Magle Chemoswed Holding AB (publ), together with its subsidiaries, operates as a contract development and manufacturing organization that serves pharmaceutical and medical device industry on a contract basis in Sweden. It provides warfarin sodium products used as anticoagulants for multiple indications; melperone hydrochloride, which is an antipsychotic agent; isradipine, a calcium channel blocker used to treat hypertension; amantadine sulfate that is used in the treatment of central nervous system disorders; and benserazide hydrochloride, which is used in combination with L-Dopa in the treatment of Parkinson’s disease. The company also offers EmboCept S, a microsphere-based medical device used in vascular occlusion of liver and lung tumors; SmartGel, a non-allergenic hydrogel based on the company’s microsphere technology; and SmartPAN, a medical device for the detection of pancreatic fluid leakage during open or minimally invasive surgical procedures.
Magle Chemoswed Holding AB (publ) Fundamentals Summary
| MAGLE fundamental statistics | |
|---|---|
| Market cap | SEK 470.88m |
| Earnings (TTM) | SEK 12.23m |
| Revenue (TTM) | SEK 171.17m |
38.5x
P/E Ratio2.8x
P/S RatioIs MAGLE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MAGLE income statement (TTM) | |
|---|---|
| Revenue | SEK 171.17m |
| Cost of Revenue | SEK 17.18m |
| Gross Profit | SEK 153.99m |
| Other Expenses | SEK 141.76m |
| Earnings | SEK 12.23m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 18, 2024
| Earnings per share (EPS) | 1.13 |
| Gross Margin | 89.96% |
| Net Profit Margin | 7.14% |
| Debt/Equity Ratio | 36.3% |
How did MAGLE perform over the long term?
See historical performance and comparison